JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $27
Exelixis Buy Rating Affirmed on Q2 Outperformance and Positive Litigation Outlook
With 73% Ownership of the Shares, Exelixis, Inc. (NASDAQ:EXEL) Is Heavily Dominated by Institutional Owners
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Unusual Options Activity: KMB, BA and Others Attract Market Bets, KMB V/OI Ratio Reaches 183.3
Morgan Stanley Maintains Exelixis(EXEL.US) With Hold Rating, Raises Target Price to $26
Morgan Stanley Sticks to Their Hold Rating for Exelixis (EXEL)
BofA Securities Maintains Exelixis(EXEL.US) With Buy Rating
Bank of America Securities Reaffirms Their Buy Rating on Exelixis (EXEL)
Exelixis' (NASDAQ:EXEL) Investors Will Be Pleased With Their 22% Return Over the Last Three Years
Ipsen Expands Exelixis Collaboration For Cabometyx In Advanced Neuroendocrine Tumors
American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond
The 23% Return Delivered to Exelixis' (NASDAQ:EXEL) Shareholders Actually Lagged YoY Earnings Growth
Ryvu Therapeutics Presents Clinical and Preclinical Data on RVU120 at the 2024 European Hematology Association Congress
Exelixis, Inc. (NASDAQ:EXEL) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Insider Sale: Director Jack Wyszomierski Sells Shares of Exelixis Inc (EXEL)
Exelixis(EXEL.US) Director Sells US$182.31K in Common Stock
Form 144 | Exelixis(EXEL.US) Director Proposes to Sell 182.34K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 4, $Exelixis(EXEL.US)$ Director JACK L WYSZOMIERSKI intends to sell 8,287 shares of its common stock on Jun 4, with a total market value of approximately $182.34K. JACK L
10 Health Care Stocks Whale Activity In Today's Session
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying